278 related articles for article (PubMed ID: 28053551)
1. Genetics of tuberous sclerosis complex: implications for clinical practice.
Caban C; Khan N; Hasbani DM; Crino PB
Appl Clin Genet; 2017; 10():1-8. PubMed ID: 28053551
[TBL] [Abstract][Full Text] [Related]
2. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
3. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
4. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
5. New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND).
Gipson TT; Johnston MV
F1000Res; 2017; 6():. PubMed ID: 28663780
[TBL] [Abstract][Full Text] [Related]
6. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing Ca
Hisatsune C; Shimada T; Miyamoto A; Lee A; Yamagata K
J Neurosci; 2021 Sep; 41(39):8134-8149. PubMed ID: 34417327
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
8. mTOR Inhibitors in Tuberous Sclerosis Complex.
Curatolo P; Moavero R
Curr Neuropharmacol; 2012 Dec; 10(4):404-15. PubMed ID: 23730262
[TBL] [Abstract][Full Text] [Related]
9. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
[TBL] [Abstract][Full Text] [Related]
10. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
11. Nursing implications for the lifelong management of tuberous sclerosis complex.
Agricola K; Tudor C; Krueger D; Franz DN
J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis.
Kim WS
Korean J Pediatr; 2011 Jun; 54(6):241-5. PubMed ID: 21949518
[TBL] [Abstract][Full Text] [Related]
13. The role of TSC1 and TSC2 proteins in neuronal axons.
Karalis V; Wood D; Teaney NA; Sahin M
Mol Psychiatry; 2024 Jan; ():. PubMed ID: 38212374
[TBL] [Abstract][Full Text] [Related]
14. Perfect match: mTOR inhibitors and tuberous sclerosis complex.
Luo C; Ye WR; Shi W; Yin P; Chen C; He YB; Chen MF; Zu XB; Cai Y
Orphanet J Rare Dis; 2022 Mar; 17(1):106. PubMed ID: 35246210
[TBL] [Abstract][Full Text] [Related]
15. Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex.
Ji S; Lin W; Wang L; Ni Z; Jin F; Zha X; Fei G
J Cancer; 2017; 8(4):555-562. PubMed ID: 28367235
[TBL] [Abstract][Full Text] [Related]
16. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
[TBL] [Abstract][Full Text] [Related]
17. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
19. [Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway].
García-Peñas JJ; Carreras-Sááez I
Rev Neurol; 2013 Feb; 56 Suppl 1():S153-61. PubMed ID: 23446718
[TBL] [Abstract][Full Text] [Related]
20. Tuberous sclerosis complex.
Henske EP; Jóźwiak S; Kingswood JC; Sampson JR; Thiele EA
Nat Rev Dis Primers; 2016 May; 2():16035. PubMed ID: 27226234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]